BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.
| Revenue (Most Recent Fiscal Year) | $4.13B |
| Net Income (Most Recent Fiscal Year) | $1.01B |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.37 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 22.74 |
| Pre-Tax Margin (Trailing 12 Months) | -9.91% |
| Net Margin (Trailing 12 Months) | -15.16% |
| Return on Equity (Trailing 12 Months) | -2.35% |
| Return on Assets (Trailing 12 Months) | -2.05% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.33 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.21 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | 1.42 |
| Book Value per Share (Most Recent Fiscal Quarter) | $92.17 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.89 |
| Earnings per Share (Most Recent Fiscal Year) | $4.15 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.10 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 239.74M |
| Free Float | 193.71M |
| Market Capitalization | $27.64B |
| Average Volume (Last 20 Days) | 0.54M |
| Beta (Past 60 Months) | 0.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.52% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |